Treatment-Resistant Depression: What to Do When Nothing Has Worked

If you've tried two or more antidepressants without meaningful improvement, you meet the standard clinical definition of treatment-resistant depression.

That phrase lands hard. It sounds like a verdict — as though your depression has been examined and declared unfixable.

It isn't that. It's a threshold. It means the standard first approach didn't suit you, and it's time to stop repeating that approach and start doing something structurally different. In practice, reaching this point usually means you now qualify for options that weren't available to you before.

This article maps out what those options actually are, in roughly the order they're typically considered — including the ones we don't provide ourselves. It also covers something almost no other article addresses: what Massachusetts insurers require before they'll approve the more advanced treatments, and why that matters for how you and your prescriber document things starting now.

If you're in crisis right now: call or text 988 for the Suicide and Crisis Lifeline, call 911, or go to your nearest emergency room. You can also reach the BEST Team at 1-800-981-4357. Please don't wait to read the rest of this page first.

First: Make Sure It's Actually Treatment Resistance

Before escalating to more intensive treatments, the clinical literature is consistent that the first step is a careful re-examination. This isn't a stalling tactic — a meaningful proportion of apparent treatment resistance turns out to be something else.

Was each trial actually adequate? An adequate trial generally means the right dose, for six to eight weeks, taken consistently. Many "failed" medications were never titrated past a starting dose, or were stopped at week three when side effects peaked. If you've been on the same low dose for months without a review, that's not treatment resistance — that's an unfinished trial.

Is the diagnosis complete? Bipolar spectrum conditions are commonly under-recognized, because hypomania rarely prompts a doctor's visit. Antidepressants alone tend to work poorly for bipolar depression. ADHD, PTSD, and obsessive-compulsive disorder can also produce depressive symptoms that don't respond to antidepressants alone.

Is something medical contributing? Thyroid dysfunction, sleep apnea, anemia, and vitamin deficiencies all produce or worsen depressive symptoms.

Is alcohol or substance use in the picture? This is common, understandable, and frequently unaddressed.

Does your metabolism explain anything? If you've had severe side effects at low doses, or several medications that seemed to do nothing at all, how your body processes those drugs may be part of the story. Pharmacogenomic testing can identify whether you metabolize certain medications unusually fast or slowly.

A thorough re-evaluation at this stage frequently changes the plan. It's worth more than a fourth prescription of the same kind.

What the Research Says About Trying Again

It's worth being honest about the numbers, because they shape the strategy.

The STAR*D trial followed patients through four sequential treatment steps. Remission rates were roughly 37% at step one, 31% at step two, 14% at step three, and 13% at step four. Cumulatively, about two-thirds of patients reached remission at some point across all four steps.

Two things follow from this, and both matter.

Persistence works. A substantial number of people who fail the first two steps still get well. Reaching step three or four is not the end of the road.

But repeating the same kind of step yields less each time. The sharp drop between step two and step three is the important signal. It suggests that after two failed medication trials, the highest-value move is usually to change the approach — add a different class of agent, add or intensify therapy, or consider a treatment that works through a different mechanism — rather than simply trying a fifth antidepressant of the same type.

This is the practical argument for looking seriously at your other options now, rather than after trial number six.

The Options, Roughly in Order

1. Optimize what you're already on

The least dramatic and most frequently skipped step. Is the current medication at a full therapeutic dose? Has it been given enough time at that dose? If you had a partial response — some improvement, not enough — pushing the dose or extending the trial may be more productive than abandoning a medication that was partly working.

2. Switch to a different class

Moving from an SSRI to an SNRI, bupropion, mirtazapine, or another class works through somewhat different mechanisms. The advantage is a clean single-medication regimen. The disadvantage is losing whatever partial benefit the current medication provided, plus a tapering period.

3. Combine two antidepressants

Rather than switching, a second antidepressant with a complementary mechanism is added. This builds on a partial response instead of discarding it, at the cost of more potential side effects.

4. Augmentation

Adding a non-antidepressant medication that boosts the antidepressant's effect. This is one of the best-evidenced strategies for treatment-resistant depression, and an expert panel at the Mayo Clinic Depression Center reached strong consensus recommending augmentation with second-generation antipsychotics as a next-step option.

Common augmenting agents include certain atypical antipsychotics, lithium, and thyroid hormone (T3).

One practical point with outsized importance: an augmentation trial is frequently a prerequisite for insurance approval of more advanced treatments later. More on this below.

5. Therapy — added or intensified

If you've spent two years cycling through prescriptions without ever starting therapy, this is not a minor gap. For many people the most effective treatment is medication and therapy, not either alone. Cognitive behavioural therapy, dialectical behaviour therapy, and behavioural activation all have evidence in depression, and the Mayo Clinic panel included psychotherapy among its recommendations.

Therapy also does something medication can't: it addresses the circumstances, patterns, and thinking that medication doesn't touch.

6. Transcranial magnetic stimulation (TMS)

A non-invasive treatment using magnetic pulses to stimulate specific brain regions, delivered in daily outpatient sessions over several weeks. It's FDA-approved for depression that hasn't responded to medication, and it appeared in the Mayo panel's strong-consensus recommendations. No anaesthesia, no systemic side effects, and patients drive themselves home.

The main costs are time — daily sessions for several weeks — and insurance approval requirements.

7. Esketamine (Spravato) and ketamine

Esketamine is a nasal spray FDA-approved for treatment-resistant depression, administered in a certified clinic with monitoring for at least two hours afterward. It works through a different mechanism than standard antidepressants and can act considerably faster. It also appeared in the Mayo panel's strong-consensus recommendations.

Intravenous ketamine is used for depression as well, but off-label — which matters practically, because insurers generally do not cover off-label ketamine while they often do cover esketamine.

8. Electroconvulsive therapy (ECT)

ECT carries a reputation shaped largely by depictions from decades ago. Modern ECT is performed under general anaesthesia with muscle relaxants, and it remains among the most effective treatments available for severe depression, particularly when there's significant risk or when other approaches have failed. Memory effects are the principal concern and should be discussed carefully.

What Massachusetts Insurers Actually Require

This is the section most articles skip entirely, and it may be the most practically useful thing here.

The advanced treatments above are gated by insurance criteria, and those criteria are stricter than most patients realize.

For esketamine (Spravato), Blue Cross Blue Shield of Massachusetts operates under Medical Policy 087, which requires that a patient has tried and had an inadequate response to four antidepressant agents from at least two different classes, plus at least one trial of an augmenting agent — an atypical antipsychotic, lithium, or T3. This is among the strictest published thresholds of any major Massachusetts payer.

Read that again, because the implication is significant: a patient who has failed four antidepressants but never tried an augmenting agent does not meet the criteria. They'd be sent back to complete an augmentation trial first.

What counts as an adequate trial is also defined. Typically that means roughly six weeks at generally accepted doses, with the patient adherent to the medication — and adherence may be verified through pharmacy fill records.

For TMS, insurers commonly require documented failure of at least two different classes of antidepressants, a treatment plan from a licensed prescriber, and prior authorization before sessions begin. Specific thresholds vary by carrier.

Medicare Part B covers esketamine in a certified setting, subject to prior authorization and eligibility criteria, with standard Part B coinsurance applying.

Why this matters right now

Your documentation trail starts today, not when you eventually want a referral.

Practical implications:

• Fill your prescriptions, even during difficult stretches. Gaps in pharmacy records can undermine an adequate-trial claim later.

• Make sure each trial is documented properly — medication, dose, duration, and outcome recorded in your chart.

• Ask your prescriber to note failed trials explicitly, rather than leaving them implied.

• If augmentation makes clinical sense, doing it sooner may also open doors later.

• Verify your own plan's criteria. Policies vary by carrier and change over time; the figures above reflect published criteria at the time of writing.

A prescriber who understands these pathways can save you months. One who doesn't may leave you technically ineligible for a treatment you'd otherwise qualify for.

How Awaken Mind Center Fits In

We should be straightforward about scope.

What we provide: comprehensive psychiatric evaluation and diagnostic review, medication management including combination and augmentation strategies, pharmacogenomic testing, individual therapy, and life coaching — across our Norwood and Braintree locations, in person and virtually.

What we don't provide: TMS, esketamine, and ECT are delivered in specialized settings. We don't offer them.

What we do about that: if your situation calls for one of those treatments, we'll say so directly, help you understand the criteria, make sure your treatment history is documented in a way that supports authorization, and coordinate the referral. We'd rather send you somewhere useful than keep you cycling through prescriptions with us.

For most people who arrive at this point, the highest-value first step is a genuinely thorough re-evaluation — because a meaningful share of treatment-resistant depression turns out to involve an incomplete diagnosis, an under-optimized medication, an untreated medical contributor, or a missing therapeutic component.

Frequently Asked Questions

How many antidepressants do I need to fail before it's called treatment-resistant? 

The general clinical definition is two or more adequate trials — the right dose, for enough time, taken consistently. Insurance criteria for specific advanced treatments are often stricter than the clinical definition.

Does treatment-resistant depression mean I'll never get better? 

No. In the largest sequential-treatment study, a substantial number of patients reached remission at the third and fourth steps, and about two-thirds reached remission at some point overall. What the data argues for is changing approach rather than repeating the same one.

Is TMS or esketamine better? 

They suit different situations. TMS involves no medication and no systemic side effects but requires daily sessions for several weeks. Esketamine can act faster but requires clinic administration with monitoring after each dose. A prescriber familiar with your history can advise which fits better.

Will my insurance cover these treatments in Massachusetts? 

Often, when criteria are met — but the criteria are demanding. BCBS MA's published esketamine policy requires four failed antidepressant trials plus an augmenting-agent trial. Requirements differ by carrier, so verify with your own plan.

Should I stop my current antidepressant while exploring other options? 

Not on your own. Several advanced treatments are used alongside an oral antidepressant, and abrupt discontinuation causes withdrawal symptoms and rebound. Any change should be planned with your prescriber.

Could genetic testing help at this stage? 

Sometimes. It can identify whether you metabolize certain medications unusually, which explains some treatment failures. It cannot predict which medication will work. It's one input among several.

Is therapy still worth trying if medication hasn't worked? 

Yes — and if you haven't had an adequate course of evidence-based therapy, that's a real gap. Therapy works through an entirely different mechanism than medication, and the combination outperforms either alone for many people.

A Careful Second Look Is Worth More Than a Fifth Prescription

If two or more medications haven't worked, the most useful next step is usually a thorough re-evaluation — diagnosis, dosing, contributing factors, and what hasn't been tried yet — rather than another prescription of the same kind.

Awaken Mind Center offers psychiatric evaluation, medication management, therapy, and pharmacogenomic testing at our Norwood and Braintree locations, with in-person and virtual appointments.

Call: 617-729-2369 or book a consultation.